Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non–small cell lung cancer

Authors

  • Min-Che Tung MD,

    1. Department of Surgery, Tung' Taichung MetroHarbor Hospital, Taichung, Taiwan, Republic of China
    2. Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan, Republic of China
    Search for more papers by this author
    • The first 2 authors contributed equally to this work.

  • Heng-Hsiung Wu PhD,

    1. Genomic Research Center, Academia Sinica, Taipei, Taiwan, Republic of China
    Search for more papers by this author
    • The first 2 authors contributed equally to this work.

  • Ya-Wen Cheng PhD,

    1. Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Republic of China
    Search for more papers by this author
  • Lee Wang PhD,

    1. School of Public Health, Chung Shan Medical University, Taichung, Taiwan, Republic of China
    Search for more papers by this author
  • Chih-Yi Chen MD, PhD,

    1. Department of Surgery, China Medical University, Taichung, Taiwan, Republic of China
    Search for more papers by this author
  • Sauh-Der Yeh MD,

    1. Graduate Institute of Clinical Medicine, Taipei Medical University, Taipei, Taiwan, Republic of China
    Search for more papers by this author
  • Tzu-Chin Wu MD, PhD,

    1. Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, Republic of China
    Search for more papers by this author
  • Huei Lee PhD

    Corresponding author
    1. Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Republic of China
    • Corresponding author: Huei Lee, PhD, Professor, Graduate Institute of Cancer Biology and Drug Discovery, Taipei Medical University, Room 5, 12F, No. 3, Park Street, Nankang District, Taipei, Taiwan 115, ROC; Fax: (011) 886-2-26558562; hl@tmu.edu.tw

    Search for more papers by this author

Abstract

BACKGROUND

Lung cancers in women, in nonsmokers, and in patients with adenocarcinoma from Asia have more prevalent mutations in the epidermal growth factor receptor (EGFR) gene than their counterparts. However, the etiology of EGFR mutations in this population remains unclear. The authors hypothesized that the human papillomavirus (HPV) type 16/18 (HPV16/18) E6 oncoprotein may contribute to EGFR mutations in Taiwanese patients with lung cancer.

METHODS

One hundred fifty-one tumors from patients with lung cancer were enrolled to determine HPV16/18 E6 and EGFR mutations using immunohistochemistry and direct sequencing, respectively. Levels of 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) in lung tumors and cells were evaluated using immunohistochemistry and liquid chromatography-mass spectrometry/mass spectrometry. An supF mutagenesis assay was used to determine H2O2-induced mutation rates of lung cancer cells with or without E6 expression.

RESULTS

Patients with E6-positive tumors had a greater frequency of EGFR mutations than those with E6-negative tumors (41% vs 20%; P = .006). Levels of 8-oxo-dG were correlated with EGFR mutations (36% vs 16%; P = .012). Two stable clones of E6-overexpressing H157 and CL-3 cells were established for the supF mutagenesis assay. The data indicated that the cells with high E6 overexpression had higher H2O2-induced SupF gene mutation rates compared with the cells that expressed lower levels of E6 and compared with vector control cells.

CONCLUSIONS

HPV16/18 E6 may contribute in part to EGFR mutations in lung cancer, at least in the Taiwanese population. Cancer 2013;119:3367–76. © 2013 American Cancer Society.

Ancillary